It is made available under a CC-BY 4.0 International license .

1 Hypothalamic Gliosis is Associated With Multiple Cardiovascular Disease Risk Factors

- 2 Authors: Justin Lo, MS^a; Susan J Melhorn, PhD^b; Sarah Kee^b; Kelsey LW Olerich, MD, PhD^c;
- 3 Alyssa Huang, MD^d; Dabin Yeum, PhD^b; Alexa Beiser, PhD^e; Sudha Seshadri, MD^f; Charles De
- 4 Carli, MD^g; Ellen A Schur, MD, MS^b
- 5
- ⁶ ^a School of Medicine, University of Washington, Seattle, WA
- 7 ^b Department of Medicine, University of Washington, Seattle, WA
- ^c Department of Obstetrics & Gynecology, Division of Maternal-Fetal Medicine, University of
 Washington, Seattle, WA
- ^d Department of Pediatrics, University of Washington, Seattle, WA
- ^e School of Public Health, Boston University, Boston, MA
- ¹² ^f Department of Neurology, University of Texas Health Science Center at San Antonio, San
- 13 Antonio, TX
- ^g Department of Neurology, University of California, Davis, Davis, CA
- 15
- 16 Short title: Hypothalamic Gliosis and Cardiometabolic Risk
- 17
- 18 Corresponding author: Ellen A Schur
- 19 <u>ellschur@uw.edu</u>
- 20 UW Medicine Diabetes Institute, 750 Republican Street, Box 358062, Seattle, WA 98109
- 21
- 22 Word count: 8392

23 Abstract

24

25 Background

- 26 Hypothalamic gliosis is mechanistically linked to obesity and insulin resistance in rodent models.
- 27 We tested cross-sectional associations between radiologic measures of hypothalamic gliosis in
- 28 humans and clinically relevant cardiovascular disease risk factors, as well as prevalent coronary
- 29 heart disease.
- 30

31 Methods

- Using brain MRI images from Framingham Heart Study participants (N=867; mean age, 55
- 33 years; 55% females), T2 signal intensities were extracted bilaterally from the region of interest
- in the mediobasal hypothalamus (MBH) and reference regions in the amygdala (AMY) and
- 35 putamen (PUT). T2 signal ratios were created in which greater relative T2 signal intensity
- 36 suggests gliosis. The primary measure compared MBH to AMY (MBH/AMY); a positive control
- 37 ratio (MBH/PUT) also assessed MBH whereas a negative control (PUT/AMY) did not. Outcomes
- were BMI, HDL-C, LDL-C, fasting triglycerides, and the presence of hypertension (n=449),
- diabetes mellitus (n=66), metabolic syndrome (n=254), or coronary heart disease (n=25).
- 40 Dietary risk factors for gliosis were assessed in a prospective analysis. Statistical testing was
- 41 performed using linear or logistic regression.
- 42

43 Results

- 44 Greater MBH/AMY T2 signal ratios were associated with higher BMI (β = 21.5 [95% Cl, 15.4–
- 45 27.6]; *P*<0.001), higher fasting triglycerides ($\beta = 1.1$ [95% Cl, 0.6–1.7]; *P*<0.001), lower HDL-C (β
- 46 = -20.8 [95% CI, -40.0 to -1.6]; P=0.034), and presence of hypertension (odds ratio, 1.2 [95%
- 47 CI, 1.1–1.4]; *P*=0.0088), and the latter two were independent of BMI. Findings for diabetes
- 48 mellitus were mixed and attenuated by adjusting for BMI. Metabolic syndrome was associated
- 49 with MBH/AMY T2 signal ratios (odds ratio, 1.3 [95% Cl, 1.1–1.6]; P<0.001). Model results were
- almost uniformly confirmed by the positive control ratios, whereas negative control ratios that
- 51 did not test the MBH were unrelated to any outcomes (all *P*≥0.05). T2 signal ratios were not
- 52 associated with prevalent coronary heart disease (all *P*>0.05), but confidence intervals were
- 53 wide. Self-reported percentages of macronutrient intake were not consistently related to future
- 54 T2 signal ratios.
- 55

56 Conclusions

- 57 Using a well-established study of cardiovascular disease development, we found evidence
- 58 linking hypothalamic gliosis to multiple cardiovascular disease risk factors, even independent of
- adiposity. Our results highlight the need to consider neurologic mechanisms to understand and
- 60 improve cardiometabolic health.
- 61
- 62 Word count: 350

It is made available under a CC-BY 4.0 International license .

63 Non-standard Abbreviations and Acronyms

64 65

AgRP agouti-related peptide

- 66 AMY amygdala
- 67 BMI body mass index
- 68 CHD coronary heart disease
- 69 CNS central nervous system
- 70 CVD cardiovascular disease
- 71 DM diabetes mellitus
- 72 FDR false discovery rate
- 73 FFQ food frequency questionnaire
- 74 FHS Framingham Heart Study
- 75 HDL-C high-density lipoprotein cholesterol
- 76 HTN hypertension
- 77 LDL-C low-density lipoprotein cholesterol
- 78 MBH mediobasal hypothalamus
- 79 MetS metabolic syndrome
- 80 MRI magnetic resonance imaging
- 81 POMC pro-opiomelanocortin
- 82 PUT putamen
- 83 PVN paraventricular nucleus
- 84 ROI region of interest
- 85 SNA sympathetic nerve activity
- 86 T1D type 1 diabetes
- 87 T2D type 2 diabetes

It is made available under a CC-BY 4.0 International license .

88 Introduction

Obesity, hypertension (HTN), metabolic syndrome (MetS), and type 2 diabetes (T2D) are well-89 90 established risk factors for increased cardiovascular disease (CVD) morbidity and mortality. However, central nervous system (CNS) involvement in the pathogenesis of CVD risk factors, 91 including obesity and T2D, is increasingly recognized.¹ A robust preclinical literature 92 demonstrates that diet-induced obesity in animal models is causally related to cellular 93 inflammatory responses in the hypothalamus.² Furthermore, T2D is linked to the remodeling of 94 extracellular matrix structures that scaffold neurons and their synaptic connections.³ In 95 96 humans, ex vivo histopathological and in vivo neuroimaging studies support that cellular and tissue-level alterations consistent with hypothalamic gliosis are present in the human 97 hypothalamus in association with obesity and metabolic disease.¹ Prospective studies further 98 99 support a role in obesity and T2D pathogenesis by showing that the extent of gliosis, defined as proliferation and inflammatory activation of glia, is associated with weight gain and progressive 100 insulin resistance in children and adults with overweight or obesity.^{4,5} Moreover, arcuate 101 102 nucleus inflammation may mediate the increased atherogenic risk associated with hypogonadism in males.⁶ Further studies have linked hypothalamic inflammation to MetS, T2D, 103 and impaired glucose tolerance.^{5,7,8} Therefore, hypothalamic inflammation and gliosis could 104 indirectly increase the risk of CVD by promoting metabolic dysregulation, chronic systemic 105 106 inflammation, and/or atherogenic lipid profiles. 107 Alternatively, diet-induced hypothalamic inflammation in the MBH and its arcuate

107 Alternatively, diet-induced hypothalamic innamination in the MBH and its arcuate 108 nucleus could directly contribute to CVD development. The arcuate nucleus receives sensory 109 inputs and transmits intra- and extra-hypothalamic communications to govern homeostatic

It is made available under a CC-BY 4.0 International license .

110	regulation of key metabolic functions including energy balance, feeding behavior, and							
111	maintenance of circulating glucose, but also sympathetic nerve activity (SNA). ⁹ The latter							
112	involves reciprocal inputs, primarily via the paraventricular nucleus, that can increase							
113	sympathetic tone, peripheral vascular resistance, and, hence, blood pressure. ¹⁰ Based on these							
114	delineated neuronal pathways, inflammation and gliosis affecting the arcuate nucleus has the							
115	potential to underlie obesity-associated increases in blood pressure and prevalence of HTN.							
116	This has yet to be investigated and offers a route, separate from the above-noted metabolic							
117	conditions, whereby CVD risk could be elevated via a CNS etiology. In summary, the							
118	accumulated literature suggests hypothalamic inflammation and gliosis could influence CVD							
119	development. We therefore investigated, in the Framingham Heart Study (FHS), the							
120	associations of multiple cardiometabolic risk factors as well as prevalent coronary heart disease							
121	(CHD) with radiologically assessed measures of hypothalamic gliosis. We also prospectively							
122	examined dietary risk factors for hypothalamic gliosis based on self-reported dietary intake.							
123								
124	Methods							
125	All data used in the analyses were shared through the FHS Repository and are available by							
126	request for approved projects. JL had full access to the data and is responsible for the integrity							
127	of the data analysis in the study.							
128	Study population							
129	In this cross-sectional study, 905 MRI images were provided from magnetic resonance imaging							
130	(MRI) exams conducted on the FHS Offspring and Generation 3 cohorts (Figure S1). The FHS is a							

131 longitudinal, multigenerational observational cohort study investigating cardiovascular risk

It is made available under a CC-BY 4.0 International license .

132	factors. FHS cohort recruitment and enrollment are described in detail elsewhere. ^{11,12} Brain MRI
133	was added to the FHS to investigate brain aging. ¹³ We evaluated 3T MRI images assessed
134	between 2012 and 2018 in relation to cardiovascular health indicators measured in the
135	Offspring (examination 9, 2011–2014, n=25) and Generation 3 (examination 2, 2009–2011,
136	n=14; examination 3, 2016–2019, n=828) cohorts. For the majority of the sample, brain MR
137	imaging was conducted in proximity to examination 3, on average, –0.3 years (range, –3.1 to
138	2.3 years) before examination 3 for Generation 3 cohort participants. For the remaining
139	participants, the MRI occurred an average of 5.6 years (range, 2.5–9.2 years) after examination
140	9 for Offspring Cohort participants and 6.4 years (range, 5.9–7.1 years) after examination 2 for
141	Generation 3 participants without examination 3 data. 35 MRI images were uninterpretable in
142	regions of interest (ROIs), while 3 MRI images were repeated scans from the same individual.
143	The total sample size included 867 individuals with unique MRI images and ratable T2-signal
144	intensities in ROIs. Those with missing data for certain covariates or outcomes were excluded
145	from relevant sub-analyses. For triglyceride analyses, we excluded individuals with fasting
146	triglyceride concentrations above 500 mg/dL (n=4).

147 Outcomes of interest

Outcomes of interest in this study were cardiovascular risk factors including body mass index (BMI), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), fasting triglycerides, HTN, diabetes mellitus (DM), and MetS, as well as prevalent coronary heart disease (CHD). BMI was calculated from height and weight measurements. HDL-C, LDL-C, and fasting (at least 8 hours prior to blood sample collection) triglycerides were measured in ethylenediaminetetraacetic acid serum tests. The presence of HTN was based on the American

It is made available under a CC-BY 4.0 International license .

154 Heart Association stage 1 and stage 2 HTN definitions as either systolic blood pressure greater 155 than or equal to 130 mmHg, diastolic blood pressure greater than or equal to 80 mmHg, and/or receiving treatment for HTN.¹⁴ DM was defined as either fasting blood glucose greater than or 156 157 equal to 126 mg/dL, random blood glucose greater than or equal to 200 mg/dL, and/or treatment for DM. Distinction between type 1 diabetes (T1D) and T2D was not ascertained but 158 most cases were assumed to be T2D, as discussed in previous literature.¹⁵ MetS was defined as 159 having 3 or more criteria of metabolic abnormalities according to the American Heart 160 Association and the National Heart, Lung, and Blood Institute definition¹⁶: 1) systolic blood 161 pressure greater than or equal to 130 mmHg, diastolic blood pressure greater than or equal to 162 85 mmHg, or receiving treatment for HTN; 2) fasting blood glucose greater than or equal to 100 163 mg/dL or receiving treatment for elevated blood glucose; 3) HDL-C less than 40 mg/dL in males 164 165 or 50 mg/dL in females or receiving treatment for low HDL-C; 4) triglycerides greater than or 166 equal to 150 mg/dL or receiving treatment for high triglycerides; 5) waist circumference greater than or equal to 102 cm for males or 88 cm for females. Finally, CHD was defined as 167 manifestations of CHD before or during the FHS study period, including myocardial infarction, 168 169 coronary insufficiency, angina pectoris, sudden death from CHD, and non-sudden death from CHD, and was adjudicated by FHS investigators. 170

171 Dietary Exposures

In a prospective cohort analysis, the relation of dietary exposures to subsequent MRI findings
was tested. Dietary exposures were collected from a Food Frequency Questionnaire (FFQ)
administered at the FHS exam prior to MRI acquisition (Offspring cohort, examination 8;
Generation 3 cohort, examination 2). Daily consumptions of the proportions of total fat, total

It is made available under a CC-BY 4.0 International license .

176 carbohydrates, total protein, total sugar, fructose, sucrose, and saturated fat of total energy 177 intake were calculated by dividing each dietary exposure intake (kilocalories consumed) by the average daily caloric intake. 51 participants were missing FFQ data and 2 participants with 178 implausible values for the proportions of total fat and saturated fat were removed from all 179 dietary analyses, leaving a total sample of N=814. There was a greater percentage of females in 180 181 the group of participants with FFQ data compared to those without; otherwise, the two groups 182 did not differ in other relevant characteristics such as age, smoking status, and BMI (data not shown). 183

184 Covariates

Age, sex, and smoking status were collected and reported in the FHS exam data. Information on

an individual's treatment status for HTN, DM, and lipid levels was determined from both self-

187 reported exam data and medication review. Physical activity was captured based on a physical

activity index derived from self-reported levels of activity during a typical 24-hour period.

189 Methods to construct the physical activity index are described in detail elsewhere.¹⁷

190 MRI Acquisition and Analysis

191 High-resolution T2-weighted axial brain images were analyzed in Horos Medical Image Software 192 by two independent raters (Figure 1). The image slice superior to the optic chiasm, with visible 193 optic tracts and mammillary bodies, was identified as the MBH slice of interest. The MBH ROI was placed bilaterally in the anterior hypothalamic area adjacent to the 3rd ventricle to 194 195 encompass the region of the arcuate nucleus. Slices inferior and superior were selected based on clear anatomical landmarks for the control ROIs (i.e., AMY and PUT). T2 signal intensities 196 197 were extracted bilaterally from the regions (i.e., MBH, AMY, and PUT). The signal intensities were then used to create ratios for the left, right, and bilateral mean for our primary measure 198

It is made available under a CC-BY 4.0 International license .

199	(MBH/AMY) T2 signal ratio assessing hypothalamic gliosis, a positive control (MBH/PUT) T2
200	signal ratio, and a negative control (PUT/AMY) T2 signal ratio. T2 signal ratios were used to
201	capture MBH T2 signal relative to gray matter reference ROIs and to account for inter-subject
202	variability in signal intensity of the T2-weighted acquisitions. Calculated ratios from individual
203	raters were averaged and used in statistical analyses. The intraclass correlations between the
204	independent raters for the MBH/AMY, MBH/PUT, and PUT/AMY ratios were 0.71, 0.82, and
205	0.91, respectively.

206 Statistical analysis

Multiple linear regression was used to analyze continuous outcomes (i.e., BMI, LDL-C, HDL-C, 207 and triglycerides); multiple logistic regression was used to analyze binary outcomes (i.e., HTN, 208 DM, MetS, and CHD). Coefficients and confidence intervals are reported as the estimated 209 210 change in outcome per 1 unit difference in the predictor variable, while odds ratios and 211 confidence intervals are reported as the estimated change in odds per 1 SD difference in the 212 predictor variable. Fasting triglyceride levels were right-skewed and natural logarithmtransformed for analysis. T2 signal ratios for the primary exposure, positive control, and 213 negative control predictors were natural logarithm transformed and used as predictors in the 214 215 models to satisfy conditions of normality. Age and sex were included as covariates in the base model (Model 1). Current smoking status was added in subsequent models (Model 2), while risk 216 217 factor treatment status was further adjusted for outcomes except MetS (Model 3). BMI was added in fully adjusted models when appropriate. Table S1 describes the full set of covariates 218 219 included in the models. We evaluated statistical significance using two-sided tests at the P<0.05 level, uncorrected for multiple comparisons for our *a prior* outcomes, to test associations with 220

It is made available under a CC-BY 4.0 International license .

and without adjustment for confounders such as BMI. Statistics were computed in R version4.2.3.

223	To test associations between dietary exposures and T2 signal ratios, both simple and							
224	multiple linear regression models were conducted adjusting for age, sex, and time interval							
225	between dietary exposure measurement and MRI measurement (years). A false discovery rate							
226	(FDR) multiple comparison correction was applied to this set of analyses at q < 0.05. To explore if							
227	the associations were modified by weight status, interaction terms between BMI categories							
228	(<25 kg/m²; ≥25 kg/m² & <30 kg/m²; ≥30 kg/m²) and each dietary exposure were added in							
229	separate regression models. Diet analysis was conducted using R version 4.0.2.							
230								
231	Results							
232	Participant characteristics							
233	Characteristics from 867 individuals are presented in Table 1. The sample averaged 55 years of							
234	age and was 55% female. The mean BMI was in the overweight range, whereas 34.6% of the							
235	sample had a BMI in the obesity range. Current smoking (5.4%), diabetes treatment (5.4%), and							
236	prevalent CHD (2.9%) were rare.							
237	Body mass index (BMI)							
238	MBH/AMY T2 signal ratios and BMI were positively associated (Figure 2A). The positive							
239	association between MBH/AMY T2 signal ratios and BMI persisted after adjusting for age, sex,							
240	smoking status, and diabetes treatment (Table 2). Coefficients estimate that a 0.1 unit increase							
241	in the natural logarithm-transformed MBH/AMY T2 signal ratio would be associated with a 2.2							

242 kg/m² (95% Cl 1.5–2.8) higher BMI. The positive control (MBH/PUT) T2 signal ratio was also

It is made available under a CC-BY 4.0 International license .

- positively associated with BMI in all models, whereas there were null associations for the
- negative control (PUT/AMY) T2 signal ratio and BMI (Table 2).
- 245 HDL cholesterol (HDL-C)
- 246 There was a negative association between MBH/AMY T2 signal ratios and HDL-C (Figure 2B).
- 247 Negative associations were present at all levels of adjustment in models testing the primary
- 248 exposure (MBH/AMY T2 signal ratio) and the positive control (MBH/PUT) T2 signal ratio (Table
- 249 2), including after adjustment for BMI. PUT/AMY T2 signal ratios were not associated with HDL-
- 250 C concentrations (Table 2).
- 251 LDL cholesterol (LDL-C)
- 252 The primary exposure T2 signal ratios were not associated with LDL-C in model 1 (Figure 2C) nor
- any further adjusted models (Table 2). The positive and negative control T2 signal ratios were
- similarly not associated with LDL-C (Table 2).

255 Triglycerides

- 256 There were positive associations between the MBH/AMY T2 signal ratios and fasting
- triglycerides in Model 1 (Figure 2D), as well as Models 2 and 3 (Table 2). However, the
- 258 magnitude of the association was reduced such that only a trend persisted after further
- adjusting for BMI in the fully adjusted model (Table 2, *P*=0.076). In contrast, MBH/PUT T2 signal
- 260 ratios were uniformly positively associated with natural logarithm-transformed fasting
- 261 triglycerides, including after adjustment for BMI. PUT/AMY T2 signal ratios were not
- significantly associated with fasting triglycerides (Table 2).

It is made available under a CC-BY 4.0 International license .

263 Hypertension

- 264 For all models, there were positive associations between MBH/AMY T2 signal ratios and the
- presence of HTN (Figure 3). Model 1 estimates that a 1 SD difference in the natural-logarithm
- transformed MBH/AMY T2 signal ratio is associated with a 1.4 (95% Cl 1.2–1.6) times greater
- 267 odds of HTN diagnosis. Positive control T2 signal ratios were also positively associated with the
- presence of HTN, except for in the fully adjusted model (P=0.12). No associations were found
- with the negative control T2 signal ratio (Figure 3).
- 270 Diabetes mellitus (DM)
- 271 MBH/AMY T2 signal ratios were not associated with prevalent DM in any models (Figure 3).
- 272 MBH/PUT T2 signal ratios were associated with higher odds of prevalent DM (Figure 3), but not
- in the fully adjusted model that included BMI (*P*=0.21). PUT/AMY T2 signal ratios were not
- associated with DM (Figure 3).

275 Metabolic syndrome (MetS)

- 276 MBH/AMY T2 signal ratios were positively associated with prevalent MetS in all models (Figure
- 277 3), including after adjustment for age, sex, smoking status, and physical activity. The MBH/PUT
- T2 signal ratios were also positively associated with prevalent MetS at all levels of adjustment,
- whereas the PUT/AMY T2 signal ratios were not associated (Figure 3).
- 280 Coronary heart disease (CHD)
- Among 25 individuals with prevalent CHD, 20 individuals were diagnosed with CHD prior to
- their MRI exam. There were no associations between the MBH/AMY T2 signal ratios and
- prevalent CHD (Figure 3), and all models returned coefficients with wide confidence intervals.

It is made available under a CC-BY 4.0 International license .

284 Neither positive nor negative control T2 signal ratios were associated with prevalent CHD

285 (Figure 3).

286 Sensitivity analyses

287 The timing of health information collection and MRI assessment across the sample varied by

individual and cohort. Results adjusted for time intervals between FHS health examination and

289 MRI examination are presented in Tables S3 and S4, and findings were unchanged from the

290 primary analysis.

291 Dietary exposures in relation to MBH gliosis

In analyses adjusting for age, sex, and time interval between dietary exposures and MRI, no
statistically significant prospective associations (Table S5) were found between self-reported

294 intake of total fat (β =0.04 [95% CI, -0.02 to 0.11]; *P*=0.19), total carbohydrates (β =-0.04 [95%

295 CI, -0.09 to 0.01]; *P*=0.15), total protein (β = 0.09 [95% CI, -0.04 to 0.22]; *P*=0.19), fructose (β =

296 -0.03 [95% Cl, -0.22 to 0.17]; P=0.78), sucrose ($\beta = -0.08$ [95% Cl, -0.20 to 0.04]; P=0.19), or

saturated fat (β =0.12 [95% CI, -0.04 to 0.29]; *P*=0.14) and the degree of MBH gliosis (natural

logarithm transformed MBH/AMY T2 signal ratio) assessed at MRI examinations conducted, on

average, 7 years after completion of FFQs. Negative associations were found between the

300 proportion of daily total carbohydrate intake (β =-0.08 [95% Cl, -0.16 to 0.00]; *P*=0.04) and

sucrose intake (β =-0.20 [95% Cl, -0.38 to -0.02]; *P*=0.03) and the positive control (MBH/PUT)

T2 signal ratio. These associations did not meet the FDR correction criteria at q<0.05. No

associations were found between dietary exposures and the negative control (PUT/AMY) T2

304 signal ratios (Table S5). Exploratory analyses demonstrated a significant interaction between

305 the BMI group and the proportion of daily saturated fat intake on the degree of MBH gliosis

It is made available under a CC-BY 4.0 International license .

306 (natural logarithm transformed MBH/AMY T2 signal ratio) after covariate adjustment (β-

- int=0.25 [95% CI, 0.04–0.46]; P-int=0.02). As shown in Figure S2, stratified analyses revealed
- opposing directions of slopes by BMI group (BMI<25 kg/m²: β =-0.31 [95% CI, -0.60 to -0.15];
- 309 *P*=0.04; 25 kg/m²≤BMI<30 kg/m²: β=0.16 [95% CI, –0.08 to 0.40]; *P*=0.20; BMI ≥30 kg/m²:
- 310 β =0.22 [95% Cl, -0.08 to 0.53]; *P*=0.14).

311 Discussion

Using a well-established study of CVD development, we found evidence linking hypothalamic 312 313 gliosis to multiple CVD risk factors. Prior human studies indicate that obesity and metabolic 314 dysregulation, including glucose intolerance and T2D, are associated with histologic and radiologic signs of MBH inflammation and gliosis.¹ In the largest sample studied to date, we 315 found strong positive associations of MBH gliosis with BMI and MetS, supporting previous 316 findings.^{7,18} Novel results linked MBH gliosis to low HDL-C and increased prevalence of HTN. 317 These associations persisted with adjustment for BMI, suggesting that it is not solely obesity-318 319 related metabolic dysfunction driving the result, but that the function of central pathways 320 regulating circulating lipids and blood pressure could be directly impacted by glial cell inflammatory responses in the MBH. Although we did not find associations between 321 hypothalamic gliosis and a clinical diagnosis of CHD, the sample size was small, and incident 322 disease was not assessed. In sum, these findings add to an expanding body of evidence 323 324 demonstrating the influence of CNS factors, namely hypothalamic inflammation and gliosis, on 325 the pathogenesis of cardiometabolic risk and, potentially, CVD itself. 326 Low levels of circulating HDL-C and high levels of LDL-C and triglycerides confer an increased risk for CVD development and are strongly associated with obesity.^{19,20} However, few 327

It is made available under a CC-BY 4.0 International license .

328	studies have closely examined the relationship of dyslipidemia to diet-induced hypothalamic
329	inflammation. A study of 41 healthy adult males found that longer MBH T2 relaxation times
330	were associated with higher LDL-C levels but not associated with HDL-C or triglyceride levels. 6 In
331	a cross-sectional study, Kreutzer et al. found no association between unilateral left-sided
332	MBH/AMY T2 signal ratios and triglyceride levels among 111 adults with and without obesity. ²¹
333	Contrary to these smaller studies, we observed a strong negative association between MBH
334	gliosis and HDL-C. The negative association was present even after adjusting for BMI, a finding
335	that is consistent with the hypothesis that the severity of hypothalamic inflammation is directly
336	related to the worsening of obesity-associated metabolic dysregulation of both peripheral
337	glucose and blood lipids. Apolipoprotein A-I deficiency in mice produces a phenotype that
338	recapitulates many features of MetS including increased adiposity, visceral and hepatic fat
339	deposition, hypertriglyceridemia, glucose intolerance, and low HDL-C and is accompanied by
340	inflammation and reactive astrocytosis in the MBH. ²² Intriguingly, administering reconstituted
341	human HDL-C normalized values of astrocyte inflammatory markers, indicating a potentially
342	protective role for HDL-C in reducing hypothalamic inflammation with concomitant
343	improvement in some features of MetS. ²² On the contrary, randomized trials of
344	pharmacotherapies to increase HDL-C levels have not been shown to decrease CVD risk in
345	humans. ^{23–25} Nonetheless, given the strong relationships between low HDL-C and altered
346	hypothalamic tissue structure in the current study, hypothalamic gliosis represents a novel,
347	largely unexplored mechanism to advance understanding of both the etiology of low HDL-C in
348	obesity and contradictory findings regarding the benefits of raising HDL-C for reducing CVD risk.
349	We also found evidence of a positive association between MBH/AMY T2 signal ratios and

It is made available under a CC-BY 4.0 International license .

fasting triglyceride concentrations. The association was attenuated when adjusting for BMI,

indicating that high levels of peripheral adiposity at least partially explain the relationship.

352 Lastly, we did not observe associations between T2 signal ratios and LDL-C. Nevertheless, the

353 MBH's role in energy homeostasis and the current findings should prompt further investigation

into dysregulation of circulating lipids by hypothalamic inflammation.

355 Preclinical evidence points to the role of the arcuate nucleus in altering blood pressure through SNA.^{10,26} High-fat diets and obesity activate the arcuate nucleus, located within the 356 MBH, to alter SNA primarily through insulin and leptin signaling.^{10,26} Both hormones bind to 357 358 pro-opiomelanocortin (POMC) and agouti-related peptide (AgRP) neurons in the arcuate nucleus, which in turn relay signals to other hypothalamic sites, such as the paraventricular 359 nucleus (PVN), an important regulator of SNA and blood pressure.^{27,28} Specifically, POMC 360 361 neurons release α -melanocyte-stimulating hormone that activates downstream melanocortin-4 362 receptors to increase SNA in the PVN, while AgRP neurons release neuropeptide Y (NPY) that suppresses sympathoinhibitory effects in the PVN.^{29–33} Our results provide novel evidence that 363 MBH gliosis, a diet-induced phenomenon, is associated with HTN in humans. While the exact 364 mechanisms remain uncertain, hyperleptinemia, hyperinsulinemia, and/or local inflammation 365 itself may exacerbate arcuate nucleus-induced SNA, thereby raising blood pressure via the well-366 defined neural circuitry outlined above. In the current study, associations were attenuated but 367 still present after adjusting for BMI, providing further rationale for investigating how 368 inflammation and gliosis in the arcuate nucleus region could evoke adiposity-independent 369 effects on neural circuits controlling blood pressure. 370

It is made available under a CC-BY 4.0 International license .

371	Hypothalamic gliosis has been linked to the development and progression of insulin
372	resistance. In a recent study in humans, Rosenbaum et al. showed the degree of MBH gliosis,
373	quantitatively assessed by MRI, was greater in individuals with obesity and impaired glucose
374	tolerance or T2D. ⁵ This result was also observed in a separate study of women with obesity and
375	T2D. ⁸ Following study subjects over time, Rosenbaum et al. found that MBH gliosis was related
376	to worsening insulin sensitivity over a 1-year follow-up period. 5 Our current study did not
377	consistently detect an association between MBH T2 signal ratios and the presence of DM—
378	however, the point estimates trended in the positive direction but wide confidence intervals
379	made the association nonsignificant. The inability to distinguish between individuals with T1D
380	and T2D and the relatively low prevalence of DM in this FHS sample may have limited the ability
381	to detect a significant association. Studies assessing incident disease are needed to investigate
382	the role that MBH gliosis might play in T2D pathogenesis.
383	MetS was strongly associated with greater evidence of MBH gliosis. This is perhaps
384	unsurprising given that it is a composite clinical definition that includes CVD risk factors that
385	were individually associated with MBH gliosis. Kullman et al. previously demonstrated that
386	individuals with MetS had higher water content in regions of the brain including the
387	hypothalamus, thalamus, and fornix. Water content in these regions, as suggested by the
388	authors, may have resulted from an inflammatory response by glial cells increasing water
389	uptake, potentially damaging local microenvironments. ⁷ Results from the present study are
390	consistent with Kullman et al. Such cross-sectional findings provide evidence that MetS and its
391	clinical components are related to hypothalamic inflammation, and potentially, structural

392 changes specific to the hypothalamus. Whether the severity of metabolic dysregulation (e.g.,

It is made available under a CC-BY 4.0 International license .

higher blood pressure, worse insulin resistance) or the presence of a greater number of CVD
risk factors is related to the degree of inflammation and structural damage presents a focus for
future investigations.

Hypothalamic gliosis is diet-induced in preclinical models.³⁴ We were unable to identify 396 consistent dietary predictors of MBH T2 signal ratios in humans in this prospective analysis. 397 However, the prospective association between lower daily proportion of total carbohydrate 398 399 consumption and greater evidence of gliosis, as assessed by the positive control T2 signal ratio, 400 suggests that the proportions of macronutrients in daily diet might be influential. Prior findings in preclinical³⁵ and human²¹ studies highlight saturated fat consumption as a possible risk factor 401 for MBH gliosis in humans. Given the inverse relationship between carbohydrate and fat 402 consumption, the current findings of greater evidence of gliosis with lower carbohydrate intake 403 404 could be seen as supportive of the role of dietary fats in instigating hypothalamic inflammation. Furthermore, the effect of saturated fat consumption on the degree of MBH gliosis was 405 modified by weight status. This result implies that those with overweight or obesity may have a 406 different susceptibility to gliosis related to saturated fat consumption than individuals 407 408 maintaining weight in the normal range. Further research capable of discerning risk and protective factors for hypothalamic gliosis (e.g., genetics) in relation to precisely measured 409 dietary exposures is needed. 410

There are several strengths to this study. This is the largest study to date providing evidence of associations between hypothalamic gliosis and multiple CVD risk factors, including novel findings linking MBH gliosis with hypertension. Our outcomes of interest were highquality data measured and collected by FHS investigators. Limitations to this study include the

It is made available under a CC-BY 4.0 International license .

415 lack of statistical power to detect associations with CHD itself in a relatively young and healthy 416 study population with few CHD cases. Additionally, participants with longstanding CHD or DM may have adapted lifestyle modification (e.g., diet changes or weight loss) with the potential to 417 418 affect hypothalamic gliosis. Furthermore, most subjects self-identified as White, limiting the interpretation of our results to a select population, and we were not powered to determine 419 420 sex-specific associations. MRI images are an indirect measure of MBH gliosis; higher T2 signal 421 intensity can be due to local edema, tumors, or autoimmune inflammation, but in communitybased participants in an observational study, these pathologies are unlikely. Imaging variability 422 from factors such as BO inhomogeneity may have limited our ability to detect smaller effect 423 sizes. Lastly, misclassification of dietary exposures could arise due to self-report methodology 424 and any changes in habitual intake that occurred during the several-year interim before MRI 425 426 images were captured.

427 In sum, the current study focuses attention on the CNS and on the evolving understanding of how weight gain might relate to increased CVD risk.^{36,37} Weight gain and/or 428 dietary factors may promote hypothalamic inflammation which acts as a shared risk factor for 429 obesity and CVD that fails to fully resolve with lifestyle changes alone. While behavioral 430 interventions that improve metabolic status do not always reduce CVD risk,³⁸ GLP-1 agonists 431 that promote substantial weight loss as well as bariatric surgery do benefit cardiovascular 432 health.^{39–41} Preclinical and human studies show improvement in hypothalamic inflammation 433 with liraglutide⁴² and bariatric surgery,^{8,43} respectively. 434

435 These robust cross-sectional findings support investigations to clarify the role of 436 hypothalamic gliosis in CVD pathogenesis. Future epidemiologic and clinical studies could

It is made available under a CC-BY 4.0 International license .

437	examine subclinical measures of disease, such as coronary artery calcium scores and carotid
438	intima-media thickness, to test whether hypothalamic gliosis is related to atherosclerosis prior
439	to the manifestation of clinical disease. Additional studies should determine whether evidence
440	of gliosis in the hypothalamus predicts incident CVD. More robust dietary assessments or
441	integration of objective biomarkers ⁴⁴ could aid efforts to discover dietary stimulators of
442	hypothalamic inflammation in humans. Finally, preclinical studies in animal models of
443	atherosclerosis and HTN will be required to determine causal mechanisms whereby glial-cell
444	mediated hypothalamic inflammation and dysfunction might drive CVD risk.
445	
446	Acknowledgements
447	From the Framingham Heart Study of the National Heart Lung and Blood Institute of the
448	National Institutes of Health and Boston University School of Medicine. This project has been
449	funded in whole or in part with Federal funds from the National Heart, Lung, and Blood
450	Institute, National Institutes of Health, Department of Health and Human Services, under
451	Contract No. 75N92019D00031. We would like to thank Yumei Feng Earley, Ph.D. for thoughtful
452	review of the manuscript and Nash Whitford for his assistance with exponential functions.
453	
454	Sources of Funding
455	This work was supported by K24HL144917 (EAS), R01DK089036 (EAS), the University of
456	Washington Nutrition and Obesity Research Center (UW NORC) P30DK035816, AG054076,
457	P30AG066546, RF1AG059421 (SS), and P30AG072972 (CD). JL was supported by the University
458	of Washington Diabetes, Obesity and Metabolism Training Program (T32DK007247).

It is made available under a CC-BY 4.0 International license .

459

460 **Disclosures**

461 EAS has provided consultation to Amgen, Inc. The other authors report no conflicts.

- 463 Supplemental Material
- 464 Figure S1-S2
- 465 Table S1–S5

It is made available under a CC-BY 4.0 International license .

466 **References**

- Sewaybricker LE, Huang A, Chandrasekaran S, Melhorn SJ, Schur EA. The Significance of
 Hypothalamic Inflammation and Gliosis for the Pathogenesis of Obesity in Humans. *Endocr Rev.* 2022;44:281–296.
- García-Cáceres C, Balland E, Prevot V, Luquet S, Woods SC, Koch M, Horvath TL, Yi C-X,
 Chowen JA, Verkhratsky A, et al. Role of astrocytes, microglia, and tanycytes in brain
 control of systemic metabolism. *Nat Neurosci*. 2019;22:7–14.
- Alonge KM, Mirzadeh Z, Scarlett JM, Logsdon AF, Brown JM, Cabrales E, Chan CK, Kaiyala
 KJ, Bentsen MA, Banks WA, et al. Hypothalamic perineuronal net assembly is required for
 sustained diabetes remission induced by fibroblast growth factor 1 in rats. *Nat Metab*.
 2020;2:1025–1033.
- Sewaybricker LE, Kee S, Melhorn SJ, Schur EA. Greater radiologic evidence of hypothalamic gliosis predicts adiposity gain in children at risk for obesity. *Obesity (Silver Spring)*.
 2021;29:1770–1779.
- 480 5. Rosenbaum JL, Melhorn SJ, Schoen S, Webb MF, De Leon MRB, Humphreys M,
 481 Utzschneider KM, Schur EA. Evidence That Hypothalamic Gliosis Is Related to Impaired
 482 Glucose Homeostasis in Adults With Obesity. *Diabetes Care*. 2021;45:416–424.
- 6. Dorfman MD, Monfeuga T, Melhorn SJ, Kanter JE, Frey JM, Fasnacht RD, Chandran A, Lala
 E, Velasco I, Rubinow KB, et al. Central androgen action reverses hypothalamic astrogliosis
 and atherogenic risk factors induced by orchiectomy and high-fat diet feeding in male
 mice. Am J Physiol Endocrinol Metab. 2023;324:E461–E475.
- Kullmann S, Abbas Z, Machann J, Shah NJ, Scheffler K, Birkenfeld AL, Häring H-U, Fritsche
 A, Heni M, Preissl H. Investigating obesity-associated brain inflammation using
 quantitative water content mapping. *Journal of Neuroendocrinology*. 2020;32:e12907.
- 490 8. van de Sande-Lee S, Melhorn SJ, Rachid B, Rodovalho S, De-Lima-Junior JC, Campos BM,
 491 Pedro T, Beltramini GC, Chaim EA, Pareja JC, et al. Radiologic evidence that hypothalamic
 492 gliosis is improved after bariatric surgery in obese women with type 2 diabetes. *Int J Obes*493 (Lond). 2020;44:178–185.
- 494 9. Jais A, Brüning JC. Arcuate Nucleus-Dependent Regulation of Metabolism—Pathways to
 495 Obesity and Diabetes Mellitus. *Endocr Rev.* 2021;43:314–328.
- 496 10. Guyenet PG, Stornetta RL, Souza GMPR, Abbott SBG, Brooks VL. Neuronal Networks in
 497 Hypertension: Recent Advances. *Hypertension*. 2020;76:300–311.

It is made available under a CC-BY 4.0 International license .

498 11. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of
499 coronary heart disease in families. The Framingham offspring study. *Am J Epidemiol*.
500 1979;110:281–290.

Splansky GL, Corey D, Yang Q, Atwood LD, Cupples LA, Benjamin EJ, D'Agostino RB, Fox CS,
 Larson MG, Murabito JM, et al. The Third Generation Cohort of the National Heart, Lung,
 and Blood Institute's Framingham Heart Study: design, recruitment, and initial
 examination. Am J Epidemiol. 2007;165:1328–1335.

Massaro JM, D'Agostino RB, Sullivan LM, Beiser A, DeCarli C, Au R, Elias MF, Wolf PA.
 Managing and analysing data from a large-scale study on Framingham Offspring relating
 brain structure to cognitive function. *Stat Med*. 2004;23:351–367.

50814. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C,509DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. 2017

510 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the

511 Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A

512 Report of the American College of Cardiology/American Heart Association Task Force on 513 Clinical Practice Guidelines. *Hypertension*. 2018;71:e13–e115.

Echouffo-Tcheugui JB, Niiranen TJ, McCabe EL, Henglin M, Jain M, Vasan RS, Larson MG,
 Cheng S. An Early-Onset Subgroup of Type 2 Diabetes: A Multigenerational, Prospective
 Analysis in the Framingham Heart Study. *Diabetes Care*. 2020;43:3086–3093.

16. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss
 RM, Savage PJ, Smith SC, et al. Diagnosis and management of the metabolic syndrome: an
 American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.
 Circulation. 2005;112:2735–2752.

Shortreed SM, Peeters A, Forbes AB. Estimating the effect of long-term physical activity on
 cardiovascular disease and mortality: evidence from the Framingham Heart Study. *Heart*.
 2013;99:649–654.

Schur EA, Melhorn SJ, Oh S-K, Lacy JM, Berkseth KE, Guyenet SJ, Sonnen JA, Tyagi V,
Rosalynn M, De Leon B, et al. Radiologic evidence that hypothalamic gliosis is associated
with obesity and insulin resistance in humans. *Obesity (Silver Spring)*. 2015;23:2142–2148.

19. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti
 S, Faiella-Tommasino J, Forman DE, et al. 2018

- 529 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the
- 530 Management of Blood Cholesterol: A Report of the American College of
- 531 Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am
- 532 *Coll Cardiol*. 2019;73:e285–e350.

It is made available under a CC-BY 4.0 International license .

Sordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a
 protective factor against coronary heart disease. The Framingham Study. *Am J Med*.
 1977;62:707–714.

536 21. Kreutzer C, Peters S, Schulte DM, Fangmann D, Türk K, Wolff S, van Eimeren T, Ahrens M,
 537 Beckmann J, Schafmayer C, et al. Hypothalamic Inflammation in Human Obesity Is
 538 Mediated by Environmental and Genetic Factors. *Diabetes*. 2017;66:2407–2415.

- 539 22. Götz A, Lehti M, Donelan E, Striese C, Cucuruz S, Sachs S, Yi C-X, Woods SC, Wright SD,
 540 Müller TD, et al. Circulating HDL levels control hypothalamic astrogliosis via apoA-I. *J Lipid* 541 *Res.* 2018;59:1649–1659.
- AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL
 cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267.
- 545 24. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T,
 546 Tomson J, Wallendszus K, Craig M, Jiang L, et al. Effects of extended-release niacin with
 547 laropiprant in high-risk patients. *N Engl J Med*. 2014;371:203–212.
- Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger
 C, Menon V, Montalescot G, et al. Evacetrapib and Cardiovascular Outcomes in High-Risk
 Vascular Disease. *N Engl J Med*. 2017;376:1933–1942.
- Stocker SD, Ferreira CB, Souza GMPR, Abbott SBG. Brain Pathways in Blood Pressure
 Regulation. *Hypertension*. 2024;81:383–386.
- 27. Rahmouni K. Cardiovascular Regulation by the Arcuate Nucleus of the Hypothalamus.
 Hypertension. 2016;67:1064–1071.
- 28. Dampney RA, Michelini LC, Li D-P, Pan H-L. Regulation of sympathetic vasomotor activity
 by the hypothalamic paraventricular nucleus in normotensive and hypertensive states. *Am J Physiol Heart Circ Physiol*. 2018;315:H1200–H1214.
- 558 29. Shi Z, Wong J, Brooks VL. Obesity: sex and sympathetics. *Biol Sex Differ*. 2020;11:10.
- 30. da Silva AA, Kuo JJ, Hall JE. Role of Hypothalamic Melanocortin 3/4-Receptors in Mediating
 Chronic Cardiovascular, Renal, and Metabolic Actions of Leptin. *Hypertension*.
 2004;43:1312–1317.
- Shi Z, Li B, Brooks VL. Role of the Paraventricular Nucleus of the Hypothalamus in the
 Sympathoexcitatory Effects of Leptin. *Hypertension*. 2015;66:1034–1041.

<sup>S64 32. Cassaglia PA, Shi Z, Li B, Reis WL, Clute-Reinig NM, Stern JE, Brooks VL. Neuropeptide Y
s65 acts in the paraventricular nucleus to suppress sympathetic nerve activity and its
baroreflex regulation.</sup> *J Physiol*. 2014;592:1655–1675.

It is made available under a CC-BY 4.0 International license .

567	33.	Shi Z, Madden CJ, Brooks VL. Arcuate neuropeptide Y inhibits sympathetic nerve activity
568		via multiple neuropathways. <i>J Clin Invest</i> . 2017;127:2868–2880.

- 569 34. Douglass JD, Dorfman MD, Thaler JP. Glia: silent partners in energy homeostasis and 570 obesity pathogenesis. *Diabetologia*. 2017;60:226–236.
- 571 35. Valdearcos M, Robblee MM, Benjamin DI, Nomura DK, Xu AW, Koliwad SK. Microglia
 572 dictate the impact of saturated fat consumption on hypothalamic inflammation and
 573 neuronal function. *Cell Rep.* 2014;9:2124–2138.
- Purnell JQ, Braffett BH, Zinman B, Gubitosi-Klug RA, Sivitz W, Bantle JP, Ziegler G, Cleary
 PA, Brunzell JD. Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1
 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of
 Diabetes Interventions and Complications (DCCT/EDIC) Study. *Diabetes Care*.
 2017;40:1756–1762.
- Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Body-Weight
 Fluctuations and Outcomes in Coronary Disease. *N Engl J Med*. 2017;376:1332–1340.
- 38. Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M,
 Crow RS, Curtis JM, Egan CM, et al. Cardiovascular effects of intensive lifestyle
 intervention in type 2 diabetes. *N Engl J Med*. 2013;369:145–154.
- 39. Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 Receptor Agonists for the
 Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. *Circulation*. 2022;146:1882–1894.
- 40. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, HardtLindberg S, Hovingh GK, Kahn SE, Kushner RF, et al. Semaglutide and Cardiovascular
 Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221–2232.
- 41. van Veldhuisen SL, Gorter TM, van Woerden G, de Boer RA, Rienstra M, Hazebroek EJ, van
 Veldhuisen DJ. Bariatric surgery and cardiovascular disease: a systematic review and metaanalysis. *Eur Heart J.* 2022;43:1955–1969.
- Liao T, Zhang S-L, Yuan X, Mo W-Q, Wei F, Zhao S-N, Yang W, Liu H, Rong X. Liraglutide
 Lowers Body Weight Set Point in DIO Rats and its Relationship with Hypothalamic
 Microglia Activation. *Obesity (Silver Spring)*. 2020;28:122–131.
- 43. Pané A, Videla L, Calvet À, Viaplana J, Vaqué-Alcázar L, Ibarzabal A, Rozalem-Aranha M,
 Pegueroles J, Moize V, Vidal J, et al. Hypothalamic Inflammation Improves Through
 Bariatric Surgery, and Hypothalamic Volume Predicts Short-Term Weight Loss Response in
 Adults With or Without Type 2 Diabetes. *Diabetes Care*. 2024;dc232213.
- 44. Prentice RL, Vasan S, Tinker LF, Neuhouser ML, Navarro SL, Raftery D, Gowda GN,
 Pettinger M, Aragaki AK, Lampe JW, et al. Metabolomics Biomarkers for Fatty Acid Intake

It is made available under a CC-BY 4.0 International license .

- and Biomarker-Calibrated Fatty Acid Associations with Chronic Disease Risk in
- 603 Postmenopausal Women. *J Nutr*. 2023;153:2663–2677.

It is made available under a CC-BY 4.0 International license .

605 Figure Legends

Figure 1. Axial brain T2-weighted image with anatomic locations of MBH and reference regions 606 607 of interest. Representative MRI images and regions of interest (ROIs). A) The amygdala was 608 identified at the level of the optic chiasm (oc) which was, on average, one slice inferior to the 609 hypothalamus. B) Inset identified in A with representative bilateral placement of ROIs in the amygdala. C) The mediobasal hypothalamus (MBH) was identified on the slice with distinct 610 optic tracts (ot) and visible mammillary bodies (mb) and is at the level of the superior colliculus 611 of the midbrain (superior to A). D) Inset identified in C with representative placement of 612 bilateral ROIs in the anterior hypothalamus, encompassing the location of the arcuate nucleus, 613 adjacent to the 3rd ventricle. E) The putamen was identified at a level of the frontal horn of the 614 lateral ventricles (with visible caudate head, internal capsule and globus pallidus). F) Inset 615 identified in E with representative placement of bilateral ROIs in the putamen. oc, optic chiasm; 616 MBH, mediobasal hypothalamus; ot, optic tract; 3V, 3rd ventricle; mb, mammillary body; fhLV, 617 618 frontal horn of the lateral ventricle; ca, caudate; it, internal capsule; gp, globus pallidus.

619

Figure 2. Sex- and age-adjusted associations of CVD risk factors with radiologic evidence of

621 hypothalamic gliosis by MBH/AMY T2 signal ratios. Scatterplots with linear fit lines of adjusted

associations between MBH/AMY T2 signal ratio and body mass index (BMI, A), HDL cholesterol

623 (HDL-C, B), LDL cholesterol (LDL-C, C), and natural logarithm transformed fasting triglycerides

624 (D). X-axis values represent MBH/AMY T2 signal ratios back-transformed from their natural

625 logarithm value in the distribution derived from the linear fit performed on the natural

626 logarithm transformed predictor variable. P-values correspond to the two-sided probability of

the estimated t-statistic for the coefficient of the predictor in Model 1. MBH, mediobasal

- 628 hypothalamus; AMY, amygdala.
- 629

630 Figure 3. Forest plot of odds ratios & 95% confidence intervals for T2 signal ratios and binary outcomes related to cardiovascular risk and coronary heart disease. Results are from multiple 631 logistic regression models. MRI-assessed T2 signal ratios were natural logarithm transformed 632 and used as model predictors: MBH/AMY (primary), MBH/PUT (positive control), and PUT/AMY 633 (negative control). Black squares represent the point estimates of the ORs for each model's 634 635 predictor, and solid lines represent 95% CIs for the ORs. ORs and 95% CIs are presented as the change in odds for the outcome per a 1 SD difference in natural logarithm-transformed T2 636 signal ratio. Arrows indicate that the width of the 95% CI lies outside of the figure axis. The 637 dashed vertical line signifies the null OR of 1. BMI, body mass index; HDL-C, high-density 638 lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ln(Triglycerides), natural 639 logarithm transformed fasting triglycerides; MBH, mediobasal hypothalamus; AMY, amygdala; 640 641 PUT, putamen. * Model 1 adjusted for age and sex. † Model 2 adjusted for model 1 covariates 642 plus smoking. ‡ Model 3 adjusted for model 2 covariates plus diabetes treatment for BMI model or lipid treatment for HDL-C, LDL-C, and natural log-transformed triglycerides models. § 643 644 Fully adjusted model includes model 3 covariates plus BMI, when appropriate.

Table 1. Study population characteristics.

	Summary (N=867)
Age, years, mean (SD)	54.9 (8.8)
Sex	
Female, n (%)	476 (54.9)
Male, n (%)	391 (45.1)
Self-reported race	
White, n (%)	856 (98.7)
Black, n (%)	1 (0.1)
Other, n (%)	10 (1.2)
Smoking status*	
Does not smoke, n (%)	819 (94.6)
Currently smokes, n (%)	47 (5.4)
FHS physical activity index, mean (SD) ⁺	36.0 (6.2)
Body mass index, kg/m ² , mean (SD)	28.6 (5.5)
BMI<25 kg/m², n (%)	240 (27.7)
25≤BMI<30 kg/m², n (%)	327 (37.7)
BMI≥30 kg/m², n (%)	300 (34.6)
Waist circumference, cm, mean (SD)	99.7 (14.4)
HDL cholesterol, mg/dL, mean (SD)‡	60.2 (20.0)
LDL cholesterol, mg/dL, mean (SD)§	106.3 (29.4)
Fasting triglycerides, mg/dL, mean (SD)‡, , #	111.8 (72.0)
Lipid treatment	
Not treated for lipids, n (%)	638 (73.6)
Treated for lipids, n (%)	229 (26.4)
Systolic blood pressure, mm Hg, mean (SD)	119.6 (14.0)
Diastolic blood pressure, mm Hg, mean (SD)**	76.0 (8.8)
Hypertension treatment***	
Not treated for hypertension, n (%)	641 (74.0)
Treated for hypertension, n (%)	225 (26.0)
Hypertension (HTN)	
Absence of HTN, n (%)	417 (48.2)
Prevalent HTN, n (%)	449 (51.8)
Blood glucose, mg/dL, mean (SD)‡	99.6 (20.0)
Diabetes mellitus treatment	
Not treated for diabetes, n (%)	820 (94.6)
Treated for diabetes, n (%)	47 (5.4)
Diabetes mellitus (DM)‡	
Absence of DM, n (%)	798 (92.4)
Prevalent DM, n (%)	66 (7.6)
Metabolic syndrome (MetS)	

It is made available under a CC-BY 4.0 International license .

Absence of MetS, n (%)	613 (70.7)
Prevalent MetS, n (%)	254 (29.3)
Coronary heart disease (CHD)	
Absence of CHD, n (%)	842 (97.1)
Prevalent CHD, n (%)	25 (2.9)
MBH/AMY T2 signal ratio, mean (SD)	1.27 (0.07)
MBH/PUT T2 signal ratio, mean (SD)****	1.72 (0.14)
PUT/AMY T2 signal ratio, mean (SD)****	0.74 (0.06)

646

647 *n=1 individual missing information about smoking status; †n=3 individuals missing information

about physical activity; ‡ n=2 individuals missing information on triglycerides, HDL cholesterol,

649 blood glucose levels, and diabetes mellitus status; § n=12 individuals missing information on

650 LDL cholesterol; ||n=3 individuals excluded with fasting triglyceride concentrations greater

than 500 mg/dL; # n=20 individuals missing fasting triglyceride concentrations; **n=1 individual

652 missing information on DBP; *** n=1 individual missing information on hypertension

653 treatment; **** n=14 individuals missing MBH/PUT & PUT/AMY T2 signal ratios.

		BMI		HDL-C		LDL-C		ln(Triglycerides)	
I Z Signai ra	tio predictor and	Coefficient	Р	Coefficient	Р	Coefficient	Р	Coefficient	Р
model		[95% CI]	value	[95%CI]	value	[95%CI]	value	[95%CI]	value
	Model 1*	22.2 [16.0, 28.3]	<0.001	-47.3 [-67.5, -27.1]	<0.001	18.2 [-16.5, 52.8]	0.30	1.2 [0.6, 1.7]	<0.00
	Model 2 ⁺	22.2 [16.0, 28.4]	<0.001	-47.3 [-67.4, -27.1]	<0.001	17.7 [-16.9, 52.4]	0.32	1.2 [0.6, 1.7]	<0.00
	Model 3‡	21.5 [15.4, 27.6]	<0.001	-46.3 [-66.2, -26.3]	<0.001	21.5 [-11.3, 54.4]	0.20	1.1 [0.6, 1.7]	<0.00
	Fully adjusted§			-20.8 [-40.0, -1.6]	0.034	12.5 [-21.2, 46.3]	0.47	0.5 [-0.0, 1.0]	0.07
	Model 1*	12.7 [8.3, 17.0]	<0.001	-34.2 [-48.3, -20.2]	<0.001	-2.0 [-26.0, 22.1]	0.87	0.9 [0.5, 1.3]	<0.00
	Model 2 ⁺	12.9 [8.5, 17.2]	<0.001	-33.6 [-47.7, -19.5]	<0.001	-1.1 [-25.2, 23.0]	0.93	0.9 [0.5, 1.2]	<0.00
IVIBH/PUT	Model 3‡	12.2 [7.9, 16.5]	<0.001	-32.3 [-46.3, -18.4]	<0.001	3.0 [-19.9, 25.9]	0.80	0.8 [0.4, 1.2]	<0.00
	Fully adjusted§			-17.9 [-31.2, -4.6]	0.0083	-3.0 [-26.3, 20.2]	0.80	0.5 [0.1, 0.8]	0.01
	Model 1*	-2.5 [-7.4, 2.4]	0.32	14.5 [-1.3, 30.3]	0.072	17.4 [-9.2, 44.0]	0.20	-0.4 [-0.8, 0.1]	0.08
	Model 2 ⁺	-2.7 [-7.7, 2.2]	0.28	13.6 [-2.2, 29.5]	0.092	16.2 [-10.5, 42.9]	0.24	-0.3 [-0.8, 0.1]	0.11
PUT/ANT	Model 3‡	-2.2 [-7.1, 2.6]	0.37	12.4 [-3.3, 28.1]	0.12	12.7 [-12.7, 38.2]	0.33	-0.3 [-0.8, 0.1]	0.13
	Fully adjusted§			9.7 [-4.8, 24.3]	0.19	13.7 [-11.7, 39.0]	0.29	-0.3 [-0.7, 0.1]	0.20

Table 2. Associations of quantitative MRI measures and continuous outcomes related to cardiovascular risk.

655

656 Results are from multiple linear regression models. MRI-assessed T2 signal ratios were natural logarithm transformed and used as

657 model predictors: MBH/AMY (primary), MBH/PUT (positive control), and PUT/AMY (negative control). Coefficient and confidence

658 intervals represent the estimated change in outcome per 1 unit difference in the log-transformed T2 signal ratio.

659

660 BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ln(Triglycerides),

661 natural logarithm transformed fasting triglycerides; MBH, mediobasal hypothalamus; AMY, amygdala; PUT, putamen.

- 662
- 663 * Model 1 adjusted for age and sex.
- 664 [†] Model 2 adjusted for model 1 covariates plus smoking.

465 ‡ Model 3 adjusted for model 2 covariates plus diabetes treatment for BMI model or lipid treatment for HDL-C, LDL-C, and natural

- 666 log-transformed triglycerides models.
- 667 § Fully adjusted model includes model 3 covariates plus BMI, when appropriate.

International license

668 Figure 1. Axial brain T2-weighted image with anatomic locations of MBH and 669 reference regions of interest.





671 Representative MRI images and regions of interest (ROIs). A) The amygdala was identified at

- the level of the optic chiasm (oc) which was, on average, one slice inferior to the hypothalamus.
- **B)** Inset identified in A with representative bilateral placement of ROIs in the amygdala. **C)** The
- 674 mediobasal hypothalamus (MBH) was identified on the slice with distinct optic tracts (ot) and
- 675 visible mammillary bodies (mb) and is at the level of the superior colliculus of the midbrain
- 676 (superior to A). D) Inset identified in C with representative placement of bilateral ROIs in the
- 677 anterior hypothalamus, encompassing the location of the arcuate nucleus, adjacent to the 3rd
- ventricle. E) The putamen was identified at a level of the frontal horn of the lateral ventricles
- 679 (with visible caudate head, internal capsule and globus pallidus). **F)** Inset identified in E with
- 680 representative placement of bilateral ROIs in the putamen.
- 681
- 682 oc, optic chiasm; MBH, mediobasal hypothalamus; ot, optic tract; 3V, 3rd ventricle; mb,
- mammillary body; fhLV, frontal horn of the lateral ventricle; ca, caudate; it, internal capsule; gp,
- 684 globus pallidus.

Figure 2. Sex- and age-adjusted associations of CVD risk factors with radiologic
 evidence of hypothalamic gliosis by MBH/AMY T2 signal ratios.



687

Scatterplots with linear fit lines of adjusted associations between MBH/AMY T2 signal ratio and body mass index (BMI, A), HDL cholesterol (HDL-C, B), LDL cholesterol (LDL-C, C), and natural logarithm transformed fasting triglycerides (D). X-axis values represent MBH/AMY T2 signal ratios back-transformed from their natural logarithm value in the distribution derived from the linear fit performed on the natural logarithm transformed predictor variable. P-values correspond to the two-sided probability of the estimated t-statistic for the coefficient of the predictor in Model 1.

696 MBH, mediobasal hypothalamus; AMY, amygdala

Figure 3. Forest plot of odds ratios & 95% confidence intervals for T2 signal ratios and binary outcomes related to cardiovascular risk and coronary heart disease.

Model	Hypertension	OR (95% CI)	Diabetes mellitus	OR (95% CI)	Metabolic syndrome	OR (95% CI)	Coronary heart disease	OR (95% CI)
MBH/AMY T2 signal ratio	i		i		i		i	
Model 1*		1.4 (1.2, 1.6)	- <u>+</u>	1.2 (1.0, 1.6)		1.3 (1.1, 1.6)	← - 1	0.7 (0.5, 1.1)
Model 2†		1.4 (1.2, 1.6)	+	1.2 (0.9, 1.6)		1.3 (1.1, 1.6)	<	0.7 (0.5, 1.1)
Model 3‡	· -•-	1.4 (1.2, 1.6)		1.1 (0.9, 1.5)	I	1.3 (1.1, 1.6)	<	0.7 (0.5, 1.1)
Fully adjusted§		1.2 (1.1, 1.4)		1.0 (0.8, 1.3)			<- ■	0.7 (0.4, 1.1)
MBH/PUT T2 signal ratio	1		1		1		1	
Model 1*		1.2 (1.1, 1.4)	¦	1.4 (1.1, 1.8)		1.4 (1.2, 1.6)		1.0 (0.7, 1.5)
Model 2†	!- - -	1.2 (1.1, 1.4)	!	1.4 (1.1, 1.8)		1.3 (1.1, 1.6)		1.0 (0.7, 1.4)
Model 3‡	i —•—	1.2 (1.1, 1.4)		1.3 (1.0, 1.7)	·	1.3 (1.1, 1.6)		1.0 (0.6, 1.4)
Fully adjusted§	÷	1.1 (1.0, 1.3)	- <u>+</u>	1.2 (0.9, 1.6)	i i			1.0 (0.6, 1.4)
PUT/AMY T2 signal ratio	1		1		1		1	
Model 1*	- + -	1.0 (0.9, 1.1)		0.8 (0.6, 1.0)		0.9 (0.8, 1.0)		0.8 (0.5, 1.2)
Model 2†		1.0 (0.9, 1.1)		0.8 (0.6, 1.1)		0.9 (0.8, 1.1)		0.8 (0.6, 1.3)
Model 3‡	- • -	1.0 (0.9, 1.1)		0.8 (0.6, 1.1)	- • +	0.9 (0.8, 1.1)		0.8 (0.6, 1.3)
Fully adjusted§	- i	1.0 (0.9, 1.2)		0.8 (0.6, 1.1)	1			0.8 (0.6, 1.2)
0.5	1	2 0.ť		2 0.	5 1 2	2	0.5 1 2	
	OR		OR		OR		OR	

Results are from multiple logistic regression models. MRI-assessed T2 signal ratios were natural logarithm transformed and used as model predictors: MBH/AMY (primary), MBH/PUT (positive control), and PUT/AMY (negative control). Black squares represent the point estimates of the ORs for each model's predictor, and solid lines represent 95% CIs for the ORs. ORs and 95% CIs are presented as the change in odds for the outcome per a 1 SD difference in natural logarithm-transformed T2 signal ratio. Arrows indicate that the width of the 95% CI lies outside of the figure axis. The dashed vertical line signifies the null OR of 1.

MBH, mediobasal hypothalamus; AMY, amygdala; PUT, putamen; OR, odds ratio, CI, confidence interval.

- * Model 1 adjusted for age and sex.
- ⁺ Model 2 adjusted for model 1 covariates plus smoking.

[‡] Model 3 adjusted for model 2 covariates plus lipid treatment for hypertension and coronary heart disease models, presence of hypertension for diabetes mellitus models, or physical activity for metabolic syndrome models.

§ Fully adjusted model includes model 3 covariates plus BMI, when appropriate.

It is made available under a CC-BY 4.0 International license